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 Vitamin D deﬁ ciency is a public health concern. Mediated by 
classical endocrine effects, vitamin D deﬁ ciency is causally 
linked with bone and calcium disorders. Non-endocrine actions 
of vitamin D are also widely recognised and these effects 
are mediated by local tissue activation of vitamin D bringing 
about intracrine effects in non-classical sites. Supported by 
large volumes of observational studies linking low circulating 
vitamin D with negative outcomes for many common disease 
states, there is growing interest that vitamin D may be central 
to the pathology and outcomes of many common diseases, 
including cardiovascular, cancer and autoimmune conditions. 
This article explores the quality of evidence linking vitamin 
D and various disease outcomes, and furthermore describes 
some of the cellular and molecular mechanisms of vitamin D 
action that may help explain some of the incongruity of data 
observed in observational versus interventional studies of 
vitamin D supplementation. 
 KEYWORDS :  Vitamin D, osteomalacia, rickets, vitamin D receptor, 
cardiovascular mortality, cancer 
 Introduction 
 Vitamin D supports an expanding plethora of references within 
scientific and clinical journals, as well as multiple general 
media reports proclaiming associations between low levels of 
circulating vitamin D and multiple health outcomes. Vitamin 
D is a steroid hormone precursor synthesised within skin 
under the action of ultraviolet B radiation (sunlight). Dietary 
availability of vitamin D is generally limited, although oily fish 
provides a good source. 
 From a clinical standpoint, vitamin D deficiency has 
historically been most widely recognised in the context of 
endocrine dysfunction, with disturbed calcium and bone 
homeostasis causally linked to rickets in children and 
osteomalacia in adults. In more recent times, ‘non-classical’ 
actions of vitamin D have been described, mediated by local, 








functions of vitamin D separate to its established endocrine 
role in calcium/bone homeostasis. It is via the former action 
that vitamin D has been considered as a potentially important 
factor in health maintenance and in many (common) disease 
states. Recognition of widespread expression of vitamin 
D receptors beyond tissues involved in classical endocrine 
pathways adds validity to the assertion that vitamin D has 
more pleiotropic effects than first considered. Additionally, 
the enzyme (1α-hydroxylase) responsible for conversion of 
inactive 25-hydroxyvitamin D to its biologically active form, 
1,25-dihydroxyvitamin D, is not exclusively expressed in the 
kidneys but is also present in other extra-renal tissues, further 
adding credibility to the non-endocrine/non-classical actions of 
vitamin D. 
 Vitamin D beyond calcium and bone 
 Numerous observational studies have demonstrated strong 
associations between low circulating concentrations of 
25-hydroxyvitamin D and many non-skeletal diseases (eg 
cardiovascular disease, certain cancers and autoimmune 
diseases) and their outcomes. Recent meta-analyses have 
highlighted these strong inverse correlations between low 
vitamin D concentrations and multiple health outcomes 
including cause-specific and all-cause mortality. 1–3 These 
same meta-analyses examined (the relatively small number of) 
randomised controlled trials of supplementation, exploring 
potential causal associations with vitamin D. Two studies 
showed small reductions in all-cause mortality in older 
individuals (5 and 11%). 1,3 Theodoratou and colleagues 2 showed 
a beneficial effect of vitamin D supplementation on birth weight 
and reduced dental caries. Cause-specific mortality was not 
influenced by supplementation in any of the meta-analyses. 
 The broad themes and conclusions drawn from these large-
scale meta-analyses were that more research was required 
and that a causal link between vitamin D status and health 
outcomes cannot be inferred. Reverse causality must also be 
considered as an explanation for observed associations as there 
is a compelling case that ‘ill health’ in its own right often results 
in reduced UV exposure and suboptimal nutritional status, 
among other factors, which may lower circulating vitamin D. 
 Additional confounding factors that make it difficult to 
derive definitive conclusions from vitamin D treatment studies 
include supplementation of populations irrespective of risk 
factors for vitamin D deficiency/insufficiency. Any potential 
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beneficial effect of supplementation may be envisaged to be 
more apparent in those with quantitatively more significant 
reductions in vitamin D. Moreover, there is little consensus 
around the target concentration of 25-hydroxyvitamin D 
that may have beneficial effects on non-classical disease 
associations, and only in a minority of studies has total vitamin 
D been measured at baseline and following supplementation to 
demonstrate effective reversal of any deficiency. 
 Due to numerous limitations, some identified above, it 
is currently very difficult to provide conclusive evidence 
regarding causality or not using the current evidence base 
of supplementation studies. Alternative approaches using 
Mendelian randomisation have been adopted in an attempt 
to reduce confounding and glean further insight into low 
circulating vitamin D and multiple health outcomes. Afzal 
and colleagues 4 looked at genetic variants of two genes 
encoding key enzyme regulators of endogenous production of 
25-hydroxyvitmimn D, dehydrocholesterol reductase ( DHCR7 ) 
and 25 hydroxylase ( CYP2R1 ) in a subgroup of 30,000 within 
a Danish cohort of 95,000. 4 Polymorphic variants in these 
two genes result in differential efficiencies in synthesising 
25-hydroxyvitamin D; thus by examining allele scores in these 
variants it was possible to determine those individuals who 
have endogenously (genetically determined) lower vitamin D, 
and any interaction this may have with a broad array of health 
outcomes. Using the approach outlined, the group modelled 
the effect of a genetically determined 20 nmol/L reduction in 
circulating 25-hydroxyvitamin D and its impact on all-cause 
and cause-specific mortality. The study demonstrated increased 
all-cause mortality (odds ratio (OR) 1.3 (95% confidence 
interval (CI) 1.06–1.61)), cancer mortality (OR 1.43 (95% 
CI 1.02–1.99)) and other-cause mortality (OR 1.44 (95% CI 
1.01–2.04)) but there was no increased cardiovascular mortality 
in those with lower vitamin D. This Mendelian randomisation 
study adds some weight to a possible causal association between 
intrinsically low vitamin D and health outcomes; however such 
large-scale genetic studies do not provide a direct surrogate for 
the gold standard of randomised controlled trials. 
 What does abrogated function of the vitamin D 
receptor tell us? 
 Mouse models of vitamin D receptor (VDR) ablation have 
abrogated vitamin D signalling with severe osteomalacia, but 
careful phenotyping reveals no increased risk of malignancies, 
immune deficits or cardiovascular pathology. 5 VDR knockout 
models do not develop spontaneous tumours although they do 
have an increased susceptibility to carcinogen-induced tumours 
of the skin and breast. 6,7 An increased risk of inflammatory 
bowel disease and reduced interferon-γ has also been shown. 8 
Observed T-cell and macrophage dysfunction is secondary 
to associated hypocalcaemia as this immune dysfunction 
resolves with correction of serum calcium. 9 VDR knockout 
mice have higher blood pressure mediated via an activated 
renin–angiotensin system. 10 
 The very rare human disease of hereditary vitamin D 
depen dent rickets is mediated by mutations in  VDR rendering 
it ineffective. There is no apparent early excess risk of cancers 
nor autoimmune conditions or hypertension in these patients. 11 
Due to rarity, the numbers of patients studied is small so no 
firm conclusions can be drawn from the human disease state. 
Taken together, however, observations from murine and human 
functional vitamin D deficiency states (via VDR ablation) do 
not clearly support a causal link between vitamin D, increased 
cancer risk, autoimmunity or significant cardiovascular 
pathology. 
 Vitamin D physiology 
 Vitamin D physiology is well characterised with respect to 
its endocrine action. 25-hydroxylated vitamin D is activated 
within the kidney to 1,25-dihydroxyvitamin D under the action 
of 1α-hydroxylase. 1,25-dihydroxyvitamin D is the active 
form of vitamin D, capable of biological effects. The active 
form circulates free or bound (discussed later) in the systemic 
circulation to target cells to achieve its endocrine effects. More 
recently, extra-renal activation of vitamin D by 1α-hydroxylase 
has been reported at sites other than the kidneys, 12 including 
cancer and immune cells, which has relevance to many disease 
states. Local tissue-specific production of 1,25-dihydroxyvitamin 
D allows intracrine actions. 
 In vitro studies provide important insight into local effects 
of 1,25-dihydroxyvitamin D. In cancer cells there is broadly 
reduced proliferation, invasion, angiogenesis and tendency 
to metastasise with corresponding enhanced apoptosis 
and differentiation. 13 In immune cells, vitamin D reduces 
inflammation, dendritic cell maturation, cytokine production 
and antigen presentation, while leading to increased 
monocyte differentiation, improved bacterial killing and 
enhanced suppressor T-cell function. 14 Overall, the  in vitro 
effects of 1,25-dihydroxyvitamin are ‘anti-cancer’ and ‘anti-
inflammatory’, which from a mechanistic standpoint support 
important putative roles of vitamin D in these disease states. 
 Vitamin D and the free hormone hypothesis 
 Vitamin D is highly lipophilic and relies on serum carrier 
proteins to ensure effective delivery to target cells. The inactive 
form of vitamin D is managed differently in different cell types 
and tissue-specific expression of 1α-hydroxylase determines 
activation to 1,25-dihydroxyvitamin D. Conventional 
laboratory assays for vitamin D measure total (25-hydroxy) 
vitamin D, which incorporates vitamin D bound to vitamin 
D binding protein (DBP, 90%), albumin (9.9%) and a very 
small fraction of free vitamin D. The ability of different 
tissues to handle the circulating forms of vitamin D is very 
different. The kidney has appropriate intracellular machinery 
(principally megalin) 15 to handle vitamin D bound to DBP, 
whereas non-renal tissues are generally less able to deal with 
this fraction of vitamin D. Some cancer cell lines are capable of 
this function. 16,17 In general, non-renal tissues are more reliant 
on the bioavailable pool of vitamin D, which incorporates 
albumin-bound and free vitamin D that constitutes only 0.1% 
of the total vitamin D pool. 25-hydroxyvitamin D binds to 
DBP with much higher affinity than 1,25-dihydroxyvitamin 
D, and thus it is likely that DBP has a much greater impact 
on 25-hydroxyvitamin D-mediated intracrine responses. In 
this way, quantitative and qualitative factors in DBP may be 
important in determining the impact of vitamin D on various 
(non-classical) health parameters. 
 Polymorphisms in DBP account for different abundances of 
binding protein and different affinities for binding vitamin D. 
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Powe and colleagues 18 studied black and white Americans and 
characterised DBP genotypes and measured concentrations of 
circulating DBP to determine whether they differed between 
races, possibly accounting for observed racial differences 
in manifestations of vitamin D deficiency. Although black 
Americans had lower total vitamin D than whites, they had 
higher bone mineral densities, higher serum calcium and 
only marginally higher parathyroid hormone concentrations. 
When polymorphic variants of DBP were taken into account, 
the estimated bioavailable vitamin D was very similar between 
black and white Americans. The authors postulated that lower 
levels of DBP in black Americans may provide protection 
against clinical manifestations of endocrine parameters of 
vitamin D deficiency despite low levels of circulating total 
25-hydroxyvitamin D. It remains to be determined what 
direct impact quantitative and qualitative changes in DBP 
may have on non-classical vitamin D actions (predominantly 
mediated via intracrine mechanisms). As it is unbound 
25-hydroxyvitamin D that drives many of the non-classical 
actions, it is likely that DBP is an important regulator and 
determinant of intracrine functions. Bioavailable vitamin D 
is therefore likely to be a better marker of clinically relevant 
vitamin D action rather than total vitamin D. 
 What target levels of total vitamin D should we 
aim for? 
 Non-classical effects of vitamin D are likely to be mediated 
via distinct intracrine actions rather than systemic endocrine 
effects. It is quite feasible therefore that target concentrations of 
total vitamin D may be different to achieve a desired endocrine 
effect compared to putative intracrine effects on immune 
function and cancer prevention for instance. 
 There is some consensus regarding optimal vitamin D 
levels to prevent endocrine disease. However, due to lack of 
consistency around causality, there is no consensus as to what 
concentration of circulating vitamin D may be optimal to 
‘prevent’ deleterious consequences in non-classical vitamin D 
pathways. Currently vitamin D supplementation is not 
advocated to prevent chronic diseases. 19 The following sections 
therefore are restricted to vitamin D treatment for prevention 
of endocrine disease in the form of musculoskeletal disease and 
disturbance of mineral ion homeostasis. 
 There is consensus between the Institute of Medicine 
guideline 20 and the National Osteoporosis Society guideline 21 
that a sufficient concentration of total vitamin D to achieve 
appropriate bone health is 50 nmol/L and that deficiency is 
defined as less than 30 nmol/L. The American Endocrine 
Society 22 derived different thresholds, recognising sufficiency 
at greater than 75 nmol/L and deficiency less than 50 nmol/L. 
The National Osteoporosis Society guideline advised treatment 
of circulating total vitamin D between 30–50 nmol/L in the 
presence of additional clinical risk factors. 21 
 Who should we test and how should we treat 
vitamin D deﬁciency? 
 A targeted, rather than population-based screening approach 
to vitamin D testing is advocated. Patients with diseases 
with outcomes that may be improved with vitamin D 
supplementation (eg osteomalacia and osteoporosis) may 
be tested as well as patients with symptoms that could be 
attributed to vitamin D deficiency (eg suspected osteomalacia 
and widespread pain). There is no absolute requirement for 
vitamin D testing in individuals who are asymptomatic but 
who are at increased risk of vitamin D deficiency; empirical 
supplementation of at risk groups should be considered. 23 
 Effective treatment of vitamin D deficiency can take many 
practical forms but there are some key aims for treatment. 
Adequate doses should be used to ensure correction of 
deficiency, clinical consequences of vitamin D deficiency 
should be reversed in a timely manner and maintenance doses 
administered to avoid relapse while avoiding toxicity. Vitamin 
D 3 is the preferred form for supplementation as vitamin D 2 is 
cleared more quickly 24 and has lower tissue bioavailability. 25 
Fixed loading doses of high-strength vitamin D (total dose 
of approximately 300,000 IU in divided doses) should be 
considered in those with severe symptoms of deficiency and in 
those requiring treatment with potent antiresorptive drugs such 
as intravenous zoledronic acid or subcutaneous denosumab. 
After loading, a maintenance dose (typically 800–2,000 IU/day) 
of vitamin D should be prescribed to avoid further deficiency. 
A maintenance dose strategy (without requirement for loading) 
can be considered in those patients with deficiency where 
timeliness of reversal of vitamin D deficiency is less pressing. 
Routine measurements of serum total vitamin D are not 
required in patients receiving supplementation. 21 
 Conclusions 
 Vitamin D deficiency remains a public health concern and it is 
accepted that in those with underlying bone diseases, achieving 
satisfactory levels throughout the year is important to optimise 
musculoskeletal outcomes. The burgeoning observational 
data linking low vitamin D with multiple chronic diseases 
and outcomes is intriguing yet there is a paucity of reliable, 
appropriately powered randomised controlled trials to help 
determine potential causality. There remain concerns around 
potential reverse causality and multiple confounders that mean 
that we should not over extrapolate clinically to recommend 
blanket supplementation to prevent non-classical diseases. For 
instance, more novel approaches to minimise confounders 
using Mendelian randomisation have provided further clues 
that support potential causality. 
 Experiments of nature and murine models of abrogated 
vitamin D function reveal no clear propensity for non-classical 
vitamin D-associated diseases. Insights into local tissue-specific 
activation of vitamin D to mediate intracrine effects in extra-
renal tissues, and the potential centrality of DBP in determining 
free hormone concentrations, provides a potential mechanism 
whereby vitamin D may mediate its non-classical actions. 
 There are many unknowns embedded within vitamin 
D metabolism and action and there remains controversy 
surrounding even the basic parameter of what constitutes 
a satisfactory circulating concentration of vitamin D. It is 
feasible that what constitutes ‘satisfactory’ for endocrine/
musculoskeletal function may be somewhat different to a 
‘satisfactory’ level to mediate putative non-classical actions. 
Clinical trials are underway that attempt to unlock the issue 
of vitamin D supplementation and potential prevention of 
chronic, non-classical diseases, and these are due to start 
reporting in 2017. ■ 
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